1.38
4.17%
-0.06
After Hours:
1.41
0.03
+2.17%
Precigen Inc stock is currently priced at $1.38, with a 24-hour trading volume of 903.07K.
It has seen a -4.17% decreased in the last 24 hours and a -1.43% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $1.43 pivot point. If it approaches the $1.38 support level, significant changes may occur.
Previous Close:
$1.44
Open:
$1.42
24h Volume:
903.07K
Market Cap:
$348.34M
Revenue:
$6.23M
Net Income/Loss:
$-95.90M
P/E Ratio:
9.20
EPS:
0.15
Net Cash Flow:
$-68.47M
1W Performance:
+4.55%
1M Performance:
-1.43%
6M Performance:
+5.34%
1Y Performance:
+13.11%
Precigen Inc Stock (PGEN) Company Profile
Name
Precigen Inc
Sector
Industry
Phone
301 556 9900
Address
20374 Seneca Meadows Parkway, Germantown, MD
Precigen Inc Stock (PGEN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
May-23-23 | Initiated | JP Morgan | Neutral |
Nov-18-22 | Initiated | Cantor Fitzgerald | Overweight |
Feb-25-21 | Initiated | Stifel | Buy |
Feb-22-21 | Initiated | Wells Fargo | Overweight |
Feb-18-21 | Initiated | B. Riley Securities | Buy |
May-08-20 | Initiated | H.C. Wainwright | Buy |
View All
Precigen Inc Stock (PGEN) Latest News
Why FactSet Research Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
Monday.com Reports Q4 Results, Joins AN2 TherapeuticsAnd Other Big Stocks Moving Lower In Monday's Pre-Market Session
Benzinga
Why Amtech Systems Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
Benzinga
Why Longboard Pharmaceuticals Shares Are Trading Higher By Around 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Benzinga
Why Wynn Resorts Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Benzinga
Precigen Inc Stock (PGEN) Financials Data
Precigen Inc (PGEN) Revenue 2024
PGEN reported a revenue (TTM) of $6.22 million for the quarter ending December 31, 2023, a -76.87% decline year-over-year.
Precigen Inc (PGEN) Net Income 2024
PGEN net income (TTM) was -$95.90 million for the quarter ending December 31, 2023, a -438.68% decrease year-over-year.
Precigen Inc (PGEN) Cash Flow 2024
PGEN recorded a free cash flow (TTM) of -$68.47 million for the quarter ending December 31, 2023, a +2.15% increase year-over-year.
Precigen Inc (PGEN) Earnings per Share 2024
PGEN earnings per share (TTM) was -$0.39 for the quarter ending December 31, 2023, a -378.57% decline year-over-year.
About Precigen Inc
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; proprietary methane bioconversion platform that turns natural gas into energy and chemical products; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch inducible gene switch that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with ZIOPHARM Oncology, Inc.; Ares Trading S.A.; Oragenics, Inc.; Intrexon T1D Partners, LLC; Intrexon Energy Partners, LLC; Intrexon Energy Partners II, LLC; Fibrocell Science, Inc.; OvaXon, LLC; S & I Ophthalmic, LLC; Harvest start-up entities; and Surterra Holdings, Inc. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.
Cap:
|
Volume (24h):